TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenax Therapeutics Inc (TENX) is not a strong buy for a beginner, long-term investor at this moment. While the stock has potential upside due to its upcoming Phase 3 trial readout and positive analyst ratings, the current financial performance, lack of recent trading signals, and mixed technical indicators suggest waiting for more clarity on the trial results or a better entry point.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 62.036, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level of 14.639, with resistance at 15.805 and support at 13.473. The stock's short-term trend suggests a 60% chance of minor gains (0.24%) in the next day but a decline of -3.1% in the next week and -5.94% in the next month.
The upcoming Phase 3 readout for TNX-103 in Q3 has the potential to significantly boost the stock price. Analysts view the drug as a multi-billion dollar opportunity if approved. Recent analyst ratings are positive, with price targets ranging from $27 to $35.
The stock has a high-risk, high-reward setup, making it less suitable for a beginner investor. No recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$15.54M, which improved by 147.96% YoY. EPS increased to -0.38, up 123.53% YoY. Despite improvements, the financials remain weak, with no revenue or gross margin.
Analysts are optimistic about Tenax Therapeutics, with Cantor Fitzgerald initiating coverage with an Overweight rating and a $35 price target, and Guggenheim raising its price target to $34. Analysts highlight the potential of TNX-103 as a first-in-class therapy for PH-HFpEF and a pivotal Phase 3 readout in Q3 2026.
